Business Wire

SER Capital Partners Closes Debut Fund, Raises $475 Million

13.9.2022 13:00:00 EEST | Business Wire | Press release

Share

SER Capital Partners (SER), a private investment firm dedicated to sustainability, today announced the final closing of its SER Capital Partners I, LP and affiliated vehicles. SER raised a total of $475 million in support of its strategy to meaningfully capitalize middle-market businesses and infrastructure assets. SER’s inaugural fundraise exceeded its stated target with the support of aligned and well-capitalized limited partners that include a diverse group of leading endowments, state pensions, insurers, health systems and family offices.

SER invests and enhances value in businesses positioned to meet the growing demand for economic and sustainable assets, products, and services across North America. SER is led by four partners – Rahul Advani, Sara Graziano, Christopher Smith and Rhem Wooten – who bring meaningful overlapping experiences to SER. Each has successfully pioneered sustainability-focused investments and held key executive operating roles at public and private businesses over the last two decades.

“We collectively built SER to meet the critical market need for an experienced and aligned private investment firm dedicated to sustainable, environmental and renewable sectors,” said Rahul Advani, SER’s founder and Managing Partner. “We are committed to economically meeting the burgeoning customer demand for decarbonized, distributed, digitized, and electrified solutions.”

SER has already directly originated investments in four portfolio companies. These businesses collectively implement and manage battery storage, EV charging infrastructure, energy efficiency and solar assets.

  • Microgrid Networks, one of SER’s portfolio companies, helps meet New York City’s critical infrastructure needs by developing and installing battery storage assets coupled with related infrastructure, such as high-speed electric vehicle charging capabilities.
  • Perfect Power, a fast-growing energy storage and renewable development business formed by SER, is active in high-demand markets across the United States.
  • Brightcore Energy, a leading provider of end-to-end clean energy solutions to the commercial and institutional market, is using SER’s investment to better enable it to help buildings transition legacy energy platforms to significantly more efficient ones.
  • SER also developed and built a portfolio of Texas battery storage assets that it exited in an M&A transaction earlier this year.

“Looking ahead, we see a myriad of compelling investment opportunities that move us beyond legacy industrial processes heavily reliant on fossil fuels and subject to extreme commodity volatility – including those benefitting from the supportive patchwork of local, state, regional and recently expanded federal policies. Importantly, we are enthusiastic about our ability to invest in teams, businesses and assets that are poised to deliver attractive returns and protect our energy security and climate future,” Advani continued.

Metric Point Capital, a boutique private capital advisory firm, served as the placement agent. DLA Piper represented SER in connection with the fund formation.

About SER Capital Partners
SER Capital Partners is an independent, middle-market private equity firm dedicated to investing in North American sustainable industrial, environmental, and renewable businesses. Over the past two decades, its team members have amassed successful experience in its targeted sectors as private equity investors and senior executives at both private and public businesses. The firm’s strategy is to actively create attractive investments underpinned by critical assets while also authentically measuring and improving key sustainability metrics in line with the UN Principles for Responsible Investing. SER is also committed to aligning interests across its investors, team members, portfolio company management teams, and communities. More is available at www.sercapitalpartners.com.

About Metric Point Capital (Member FINRA and SIPC)
Metric Point is a boutique private capital advisory firm that specializes in raising institutional capital and executing transactions across the full spectrum of primaries, secondaries, and other liquidity solutions for alternative investment managers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

SER Capital Partners
Gil Melman
(713) 304-2396
gmelman@sercapitalpartners.com

Metric Point Capital
Alex Leykikh, Partner
(860) 478-7359
aleykikh@metricpoint.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HTEC Research: Only One in Three Healthcare Organizations is Ready to Scale AI28.4.2026 16:22:00 EEST | Press release

AI is already embedded across healthcare and life sciences. Most organizations are deploying it, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428872907/en/ HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. AI is already embedded across healthcare and life sciences. Most organizations are deploying AI, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany,

JPMorganChase Named First-Ever Global Banking Partner of the Olympic Games28.4.2026 16:00:00 EEST | Press release

The International Olympic Committee (IOC) and JPMorganChase today announced a landmark Worldwide Olympic Partnership, making JPMorganChase the first Global Banking Partner in Olympic history. The partnership includes the Los Angeles 2028 Olympic and Paralympic Games (LA28 Games) and the French Alps 2030 Olympic and Paralympic Winter Games. The firm has also reached an agreement with LA28 to become the Official Bank of Team USA and LA28, and a Founding Partner of the LA28 Games. The partnership reflects a shared commitment to ambition and excellence, and places athletes and communities at its core. Kirsty Coventry, President of the IOC, commented: “JPMorganChase is the first Global Partner from the banking sector in Olympic history, and we are proud to welcome them to the Worldwide Olympic Partner programme. This partnership reflects our shared values of ambition, excellence and will support the Olympic Movement and sport around the world. JPMorganChase’s global reach and expertise will

BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs28.4.2026 16:00:00 EEST | Press release

BlueSnap, powered by Payroc, today announced the availability of local acquiring in New Zealand, expanding its global payment orchestration capabilities and enabling businesses to process transactions domestically. Local acquiring allows businesses with a legal entity in New Zealand to process payments through domestic acquiring banks rather than routing transactions cross-border. This helps increase authorization rates, reduce payment failures, and lower transaction costs, critical factors for businesses selling into the region. Why Local Acquiring in New Zealand Matters For B2B and B2C businesses operating globally, cross-border payments often lead to higher fees and lower approval rates. Building local acquiring infrastructure independently requires managing multiple bank relationships, compliance, and integrations, making it costly and complex. BlueSnap simplifies this by providing local acquiring through a single platform, allowing businesses with a legal entity in New Zealand to

Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin ® Delivery System for Overactive Bladder28.4.2026 15:42:00 EEST | Press release

Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 15:28:00 EEST | Press release

CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye